FDA panel votes for tougher restrictions on hydrocodone

FDA panel votes for tougher restrictions on hydrocodone
A U.S. Food and Drug Administration advisory panel met Thursday and Friday to discuss the fate of certain painkillers that contain the opioid known as hydrocodone, concluding in a vote in favor of moving hydrocodone combination products into the more restrictive Schedule II category of controlled substances.

(HealthDay)—A U.S. Food and Drug Administration advisory panel met Thursday and Friday to discuss the fate of certain painkillers that contain the opioid known as hydrocodone, concluding in a vote in favor of moving hydrocodone combination products into the more restrictive Schedule II category of controlled substances.

The hydrocodone combination products include the commonly prescribed Vicodin, Lortab, and Norco.

The U.S. (DEA) requested that an FDA conduct the review. Currently, hydrocodone combination drugs are classified as Schedule III drugs but the agency wants them recategorized into the more tightly controlled Schedule II designation. Other opioid medications, including Oxycontin and Percocet, are already classified in the higher Schedule II category.

"In making a determination on whether to control or reschedule a drug, the DEA must consider eight factors: (1) the drug's actual or relative potential for abuse, (2) scientific evidence of its pharmacological effect, if known, (3) the state of current scientific knowledge regarding the drug or other substance, (4) its history or current pattern of abuse, (5) the scope, duration, and significance of abuse, (6) what, if any, risk there is to the public health, (7) its psychic or physiological dependence liability, (8) whether the substance is an immediate precursor of a substance already controlled under this title," according to the Addendum to the FDA Background Document for the Jan. 24 to 25, 2013, and Risk Management Advisory Committee Meeting.

More information: More Information

add to favorites email to friend print save as pdf

Related Stories

Senator warns FDA on danger of newest painkillers

Jan 08, 2012

Following fatal shootings in two New York pharmacy robberies, a U.S. senator is warning that a new batch of "super painkillers" now under review could force repeats of recent violent robberies that left six people dead.

FDA cracks down on hydrocone products

Sep 29, 2007

The U.S. Food and Drug Administration says it will start taking enforcement action against companies marketing unapproved hydrocodone products.

US panel opposes pure hydrocodone painkiller

Dec 09, 2012

(AP)—U.S. government health experts overwhelmingly voted against a stronger version of hydrocodone on Friday, questioning the need for a new form of one of most widely abused prescription painkillers.

Recommended for you

Added benefit of vedolizumab is not proven

7 minutes ago

Vedolizumab (trade name Entyvio) has been approved since May 2014 for patients with moderately to severely active Crohn disease or ulcerative colitis. In an early benefit assessment pursuant to the Act on the Reform of the ...

Seaweed menace may yield new medicines

23 hours ago

An invasive seaweed clogging up British coasts could be a blessing in disguise. University of Greenwich scientists have won a cash award to turn it into valuable compounds which can lead to new, life-saving drugs.

User comments